Efficient/JJ
Strategy/NN
to/TO
Identify/VB
Gene-Gene/NN
Interactions/NNS
and/CC
Its/PRP$
Application/NN
to/TO
Type/NN
2/CD
Diabetes/NNS
./.
====================
Over/RB
the/DT
past/NN
decade/NN
,/,
the/DT
detection/NN
of/IN
gene-gene/NN
interactions/NNS
has/VBZ
become/VBN
more/RBR
and/CC
more/RBR
popular/JJ
in/IN
the/DT
field/NN
of/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
./.
====================
The/DT
goal/NN
of/IN
the/DT
GWAS/NN
is/VBZ
to/TO
identify/VB
genetic/JJ
susceptibility/NN
to/TO
complex/NN
diseases/NNS
by/IN
assaying/VBG
and/CC
analyzing/VBG
hundreds/VBZ
of/IN
thousands/NNS
of/IN
single-nucleotide/JJ
polymorphisms/NNS
./.
====================
However/RB
,/,
such/JJ
tests/NNS
are/VBP
computationally/RB
demanding/VBG
and/CC
methodologically/RB
challenging/VBG
./.
====================
Recently/RB
,/,
a/DT
simple/JJ
but/CC
powerful/JJ
method/NN
,/,
named/VBN
“/NN
BOolean/JJ
Operation-based/JJ
Screening/JJ
and/CC
Testing/JJ
”/CD
(/(
BOOST/NN
)/)
,/,
was/VBD
proposed/VBN
for/IN
genome-wide/NN
gene-gene/NN
interaction/NN
analyses/NNS
./.
====================
BOOST/NN
was/VBD
designed/VBN
with/IN
a/DT
Boolean/JJ
representation/NN
of/IN
genotype/NN
data/NNS
and/CC
is/VBZ
approximately/RB
equivalent/JJ
to/TO
the/DT
log-linear/JJ
model/NN
./.
====================
It/PRP
is/VBZ
extremely/RB
fast/JJ
,/,
and/CC
genome-wide/NN
gene-gene/NN
interaction/NN
analyses/NNS
can/MD
be/VB
completed/VBN
within/IN
a/DT
few/JJ
hours/NNS
./.
====================
However/RB
,/,
BOOST/NN
can/MD
not/RB
adjust/JJ
for/IN
covariate/NN
effects/NNS
,/,
and/CC
its/PRP$
type-1/NN
error/NN
control/NN
is/VBZ
not/RB
correct/VB
./.
====================
Thus/RB
,/,
we/PRP
considered/VBD
two-step/JJ
approaches/NNS
for/IN
gene-gene/NN
interaction/NN
analyses/NNS
./.
====================
First/RB
,/,
we/PRP
selected/VBD
gene-gene/NN
interactions/NNS
with/IN
BOOST/NN
and/CC
applied/VBD
logistic/JJ
regression/NN
with/IN
covariate/NN
adjustments/NNS
to/TO
select/VB
gene-gene/NN
interactions/NNS
./.
====================
We/PRP
applied/VBD
the/DT
two-step/JJ
approach/NN
to/TO
type/NN
2/CD
diabetes/NNS
(/(
T2D/NN
)/)
in/IN
the/DT
Korea/NN
Association/NN
Resource/NN
(/(
KARE/NN
)/)
cohort/VBP
and/CC
identified/VBD
some/DT
promising/VBG
pairs/NNS
of/IN
single-nucleotide/JJ
polymorphisms/NNS
associated/VBN
with/IN
T2D/NN
./.
====================
The/DT
concept/NN
of/IN
epistasis/NN
,/,
generally/RB
defined/VBN
as/IN
interactions/NNS
among/IN
different/JJ
genes/NNS
,/,
was/VBD
first/JJ
introduced/JJ
in/IN
1909/CD
by/IN
William/JJ
Bateson/NN
to/TO
describe/VB
the/DT
latent/JJ
effect/NN
of/IN
one/CD
locus/NN
over/IN
another/DT
locus/NN
./.
====================
A/DT
quantitative/JJ
definition/NN
to/TO
the/DT
interaction/NN
was/VBD
proposed/VBN
in/IN
1918/CD
by/IN
R.A./NNP
Fisher/RB
as/IN
a/DT
statistical/JJ
deviation/NN
from/IN
the/DT
additive/JJ
effects/NNS
of/IN
two/CD
loci/NNS
on/IN
a/DT
phenotype/NN
./.
====================
This/DT
definition/NN
enabled/VBD
interaction/NN
analyses/NNS
by/IN
testing/VBG
whether/IN
products/NNS
of/IN
multiple/JJ
genotypes/NNS
are/VBP
statistically/RB
associated/VBN
with/IN
phenotypes/NNS
./.
====================
More/RBR
definitions/NNS
about/RB
the/DT
gene-gene/NN
interaction/NN
have/VBP
been/VBN
proposed/VBN
,/,
but/CC
some/DT
are/VBP
still/RB
not/RB
clearly/RB
understood/VBN
./.
====================
The/DT
statistical/JJ
gene-gene/NN
interaction/NN
has/VBZ
often/RB
been/VBN
confused/VBN
with/IN
a/DT
biological/JJ
gene-gene/NN
interaction/NN
./.
====================
Particularly/RB
,/,
the/DT
inference/NN
on/IN
a/DT
biological/JJ
mechanism/NN
is/VBZ
complicated/VBN
because/IN
of/IN
the/DT
lack/NN
of/IN
direct/JJ
correspondence/NN
between/IN
statistical/JJ
and/CC
biological/JJ
interactions/NNS
[/(
1/CD
]/)
./.
====================
In/IN
general/JJ
,/,
statisticians/NNS
define/VBP
a/DT
statistical/JJ
interaction/NN
as/IN
a/DT
departure/NN
from/IN
additivity/NN
in/IN
a/DT
linear/JJ
model/NN
using/VBG
a/DT
selected/VBN
measurement/NN
scale/NN
[/(
2/CD
]/)
./.
====================
However/RB
,/,
as/IN
was/VBD
pointed/VBN
by/IN
Wang/NN
et/FW
al/JJ
./.
====================
[/(
3/CD
]/)
,/,
if/IN
one/CD
aims/NNS
to/TO
infer/VB
biological/JJ
interactions/NNS
,/,
statistically/RB
modeled/JJ
interactions/NNS
and/CC
main/JJ
effect/NN
terms/NNS
should/MD
not/RB
be/VB
interpreted/VBN
separately/RB
[/(
2/CD
]/)
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
detected/VBD
gene-gene/NN
interactions/NNS
with/IN
a/DT
likelihood/JJ
ratio/NN
test/NN
./.
====================
Genotype/NN
scores/VBZ
for/IN
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
pairs/NNS
were/VBD
considered/VBN
nominal/JJ
variables/NNS
,/,
and/CC
nine/CD
different/JJ
levels/NNS
were/VBD
assumed/VBN
for/IN
a/DT
full/JJ
model/NN
./.
====================
For/IN
a/DT
reduced/JJ
model/NN
,/,
we/PRP
considered/VBD
three/CD
levels/NNS
for/IN
each/DT
SNP/NN
,/,
and/CC
thus/RB
,/,
our/PRP$
likelihood/NN
ratio/NN
tests/NNS
followed/VBN
a/DT
chi-square/JJ
distribution/NN
with/IN
4/CD
degrees/NNS
of/IN
freedom/JJ
./.
====================
Therefore/RB
,/,
the/DT
proposed/JJ
method/NN
can/MD
detect/VB
biological/JJ
interactions/NNS
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
biological/JJ
interactions/NNS
include/VBP
statistical/JJ
interactions/NNS
./.
====================
The/DT
method/NN
of/IN
detecting/VBG
gene-gene/NN
interactions/NNS
has/VBZ
attracted/VBN
much/RB
attention/NN
in/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
./.
====================
Including/VBG
logistic/JJ
regression/NN
analysis/NN
for/IN
detecting/VBG
gene-gene/NN
interactions/NNS
,/,
new/JJ
methods/NNS
,/,
like/IN
comparing/VBG
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
in/IN
case/NN
and/CC
control/NN
groups/NNS
,/,
have/VBP
been/VBN
recently/RB
proposed/VBN
[/(
4/CD
]/)
./.
====================
However/RB
,/,
analyzing/VBG
a/DT
large/JJ
number/NN
of/IN
SNPs/NNS
in/IN
a/DT
GWAS/JJ
is/VBZ
computationally/RB
very/RB
intensive/JJ
,/,
and/CC
various/JJ
approaches/NNS
,/,
such/JJ
as/IN
MDR/NN
[/(
5/CD
]/)
,/,
BEAM/NN
[/(
6/CD
]/)
,/,
Random/JJ
Jungle/NN
[/(
7/CD
]/)
,/,
PLINK/NN
[/(
8/CD
]/)
,/,
and/CC
BOolean/JJ
Operation-based/JJ
Screening/JJ
and/CC
Testing/JJ
(/(
BOOST/NN
)/)
,/,
have/VBP
been/VBN
proposed/VBN
to/TO
enable/JJ
gene-gene/NN
interactions/NNS
on/IN
a/DT
genome-wide/JJ
scale/JJ
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
considered/VBD
BOOST/NN
method/NN
,/,
proposed/VBN
by/IN
Wan/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
./.
====================
BOOST/NN
uses/VBZ
a/DT
non-iteratively/RB
estimated/VBN
measure/VB
that/DT
is/VBZ
approximately/RB
equal/JJ
to/TO
the/DT
maximum/NN
likelihood/NN
estimators/NNS
for/IN
a/DT
log-linear/JJ
model/NN
,/,
and/CC
it/PRP
is/VBZ
used/VBN
to/TO
select/VB
pairs/NNS
of/IN
SNPs/NNS
with/IN
a/DT
specified/VBN
threshold/JJ
./.
====================
There/EX
is/VBZ
an/DT
updated/JJ
method/NN
,/,
graphical/JJ
processing/NN
units/NNS
BOOST/NN
(/(
GBOOST/NN
)/)
,/,
which/WDT
is/VBZ
a/DT
BOOST/NN
method/NN
implemented/VBD
for/IN
a/DT
graphical/JJ
processing/NN
units/NNS
framework/NN
for/IN
enabling/VBG
parallel/NN
computing/VBG
to/TO
achieve/VB
massive/JJ
assignment/NN
in/IN
a/DT
fast/JJ
manner/NN
[/(
10/CD
]/)
./.
====================
GBOOST/NN
achieves/VBZ
a/DT
40-fold/JJ
speedup/NN
compared/VBN
with/IN
BOOST/NN
./.
====================
However/RB
,/,
in/IN
the/DT
algorithm/NN
of/IN
BOOST/NN
,/,
covariates/VBZ
other/JJ
than/IN
SNPs/NNS
can/MD
not/RB
be/VB
considered/VBN
./.
====================
We/PRP
need/VBD
a/DT
more/RBR
flexible/JJ
approach/NN
to/TO
improve/VB
the/DT
power/NN
of/IN
the/DT
model/NN
./.
====================
Here/RB
,/,
we/PRP
propose/VBP
an/DT
efficient/JJ
strategy/NN
that/DT
combines/NNS
the/DT
BOOST/NN
screening/NN
stage/NN
and/CC
logistic/JJ
regression/NN
method/NN
./.
====================
Logistic/JJ
regression/NN
generally/RB
shows/VBZ
good/JJ
statistical/JJ
power/NN
for/IN
a/DT
wide/JJ
spectrum/NN
of/IN
epistasis/NN
./.
====================
Screening/VBG
with/IN
BOOST/NN
is/VBZ
a/DT
computationally/RB
efficient/JJ
screening/NN
method/NN
,/,
and/CC
a/DT
genome-wide/NN
search/VBP
can/MD
be/VB
completed/VBN
within/IN
a/DT
few/JJ
hours/NNS
./.
====================
A/DT
follow-up/JJ
stage/NN
of/IN
logistic/JJ
regression/NN
with/IN
covariates/NNS
would/MD
improve/VB
the/DT
statistical/JJ
power/JJR
of/IN
the/DT
model/NN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
first/RB
review/NN
the/DT
BOOST/NN
method/NN
and/CC
apply/RB
the/DT
proposed/JJ
two-stage/JJ
approach/NN
to/TO
type/NN
2/CD
diabetes/NNS
(/(
T2D/NN
)/)
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
This/DT
analysis/NN
of/IN
gene-gene/NN
interactions/NNS
on/IN
a/DT
genome-wide/JJ
scale/NN
with/IN
BOOST/NN
was/VBD
completed/VBN
within/IN
42/CD
hours/NNS
,/,
and/CC
we/PRP
also/RB
identified/VBD
several/JJ
pairs/NNS
of/IN
SNPs/NNS
associated/VBN
with/IN
T2D/NN
./.
====================
T2D/NN
is/VBZ
the/DT
most/JJS
common/JJ
form/NN
of/IN
diabetes/NNS
,/,
and/CC
unlike/IN
people/NN
with/IN
type/NN
1/CD
diabetes/VBZ
,/,
T2D/NN
patients/NNS
make/VBP
insulin/NN
./.
====================
However/RB
,/,
either/CC
their/PRP$
pancreas/NN
does/VBZ
not/RB
make/VB
enough/IN
insulin/NN
or/CC
the/DT
body/NN
can/MD
not/RB
use/VB
the/DT
insulin/NN
well/RB
enough/IN
./.
====================
The/DT
prevalence/NN
of/IN
T2D/NN
has/VBZ
increased/VBN
rapidly/RB
in/IN
recent/JJ
years/NNS
./.
====================
The/DT
prevalence/NN
of/IN
T2D/NN
in/IN
Korea/NN
was/VBD
estimated/VBN
to/TO
be/VB
7.3/CD
%/NN
(/(
in/IN
people/JJ
over/IN
20/CD
years/NNS
of/IN
age/NN
)/)
in/IN
2005/CD
,/,
and/CC
the/DT
rate/NN
of/IN
patients/NNS
with/IN
T2D/NN
is/VBZ
expected/VBN
to/TO
increase/VB
dramatically/RB
from/IN
7.08/CD
%/NN
in/IN
2010/CD
to/TO
about/RB
10.85/CD
%/NN
by/IN
2030/CD
[/(
11/CD
]/)
./.
====================
Even/RB
more/RBR
and/CC
more/RBR
children/NN
are/VBP
being/VBG
diagnosed/VBN
with/IN
T2D/NN
./.
====================
Environmental/JJ
effects/NNS
,/,
like/IN
obesity/NN
and/CC
lack/NN
of/IN
physical/JJ
activity/NN
,/,
are/VBP
two/CD
of/IN
the/DT
most/JJS
common/JJ
causes/VBZ
of/IN
T2D/NN
,/,
and/CC
the/DT
increasing/VBG
prevalence/NN
may/MD
be/VB
related/JJ
with/IN
them/PRP
./.
====================
It/PRP
is/VBZ
also/RB
known/VBN
that/IN
T2D/NN
has/VBZ
considerable/JJ
heritability/NN
,/,
which/WDT
indicates/VBZ
a/DT
genetic/JJ
effect/NN
./.
====================
Until/IN
now/RB
,/,
genetic/JJ
variants/NNS
in/IN
nearly/RB
70/CD
loci/NNS
have/VBP
been/VBN
identified/VBN
for/IN
T2D/NN
./.
====================
Some/DT
variants/NNS
from/IN
genes/NNS
,/,
such/JJ
as/IN
KCNQ1/NN
[/(
12/CD
]/)
,/,
KCNJ11/NN
,/,
PPARG/NN
,/,
NRF1/NN
,/,
IDE/NN
,/,
TCF7L2/NN
,/,
CDKAL1/NN
,/,
HHEX/NN
,/,
IGF2BP2/NN
,/,
CDKN2A/B/NN
,/,
and/CC
SLC30A8/NN
[/(
13/CD
]/)
,/,
were/VBD
reported/VBN
as/IN
significant/JJ
susceptible/JJ
genes/NNS
to/TO
T2D/NN
in/IN
the/DT
East/JJ
Asian/JJ
population/NN
./.
====================
To/TO
detect/VB
the/DT
relation/NN
between/IN
gene-gene/NN
interactions/NNS
and/CC
T2D/NN
phenotype/NN
,/,
we/PRP
performed/VBD
a/DT
gene-gene/JJ
interaction/NN
analysis/NN
with/IN
the/DT
proposed/JJ
two-stage/JJ
analysis/NN
./.
====================
We/PRP
analyzed/VBD
8,842/CD
participants/NNS
(/(
4,183/CD
males/NNS
and/CC
4,659/CD
females/NNS
)/)
with/IN
352,228/CD
autosomal/JJ
SNPs/NNS
collected/JJ
from/IN
the/DT
Korea/NN
Association/NN
Resource/NN
project/VB
(/(
KARE/NN
)/)
./.
====================
We/PRP
found/VBD
some/DT
promising/VBG
gene-gene/NN
interactions/NNS
with/IN
the/DT
proposed/JJ
method/NN
,/,
and/CC
they/PRP
will/MD
be/VB
investigated/VBN
further/RBR
in/IN
our/PRP$
future/JJ
follow-up/JJ
studies/NNS
./.
====================
The/DT
KARE/NN
cohort/NN
====================
The/DT
KARE/NN
project/VB
started/VBD
in/IN
2007/CD
and/CC
recruited/VBN
10,000/CD
participants/NNS
aged/JJ
between/IN
49/CD
to/TO
60/CD
years/NNS
from/IN
Ansung/JJ
and/CC
Ansan/NN
,/,
in/IN
the/DT
Gyeonggi/NN
Province/NN
of/IN
South/NN
Korea/NN
./.
====================
About/RB
50/CD
million/NN
autosomal/JJ
SNPs/NNS
were/VBD
genotyped/VBN
with/IN
the/DT
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
arrary/NN
5.0/CD
[/(
14/CD
]/)
./.
====================
In/IN
total/JJ
,/,
8,842/CD
individuals/NNS
with/IN
352,228/CD
SNPs/NNS
are/VBP
available/JJ
./.
====================
In/IN
our/PRP$
GWASs/NNS
,/,
we/PRP
discarded/VBD
SNPs/NNS
for/IN
which/WDT
the/DT
Hardy-Weinberg/JJ
equilibrium/NN
p-values/NNS
were/VBD
less/RBR
than/IN
10–5/CD
,/,
the/DT
genotype/NN
calling/JJ
rates/NNS
were/VBD
less/RBR
than/IN
95/CD
%/NN
,/,
and/CC
the/DT
minor/JJ
allele/NN
frequencies/NNS
were/VBD
less/RBR
than/IN
0.05/CD
./.
====================
We/PRP
also/RB
eliminated/VBD
subjects/NNS
with/IN
gender/NN
inconsistencies/VBZ
,/,
those/DT
whose/WP$
identity/NN
by/IN
state/NN
was/VBD
more/RBR
than/IN
0.8/CD
,/,
and/CC
those/DT
whose/WP$
calling/JJ
rates/NNS
were/VBD
less/RBR
than/IN
95/CD
%/NN
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
analyzed/VBD
8,773/CD
participants/NNS
(/(
4,117/CD
males/NNS
and/CC
4,656/CD
females/NNS
)/)
with/IN
304,245/CD
SNPs/NNS
./.
====================
Definition/NN
of/IN
T2D/NN
====================
An/DT
individual/JJ
was/VBD
coded/VBN
as/IN
a/DT
T2D/NN
patient/NN
if/IN
the/DT
condition/NN
satisfied/JJ
the/DT
World/NN
Health/NN
Organization/NN
(/(
WHO/NN
)/)
diabetes/VBZ
diagnostic/JJ
criteria/NNS
:/:
fasting/VBG
plasma/NN
glucose/NN
(/(
glu0/NN
)/)
≥/RB
126/CD
mg/dL/NN
,/,
plasma/NN
glucose/NN
(/(
glu120/NN
)/)
≥/RB
200/CD
mg/dL/NN
2/CD
h/NN
after/IN
an/DT
oral/JJ
dose/NN
,/,
or/CC
glycated/JJ
hemoglobin/NN
(/(
HbA1c/NNP
)/)
≥/RB
6.5/CD
%/NN
./.
====================
A/DT
total/JJ
of/IN
1,169/CD
subjects/NNS
were/VBD
diagnosed/VBN
as/IN
cases/NNS
,/,
and/CC
the/DT
other/JJ
individuals/NNS
were/VBD
considered/VBN
controls/NNS
./.
====================
Notations/NNS
====================
We/PRP
assume/VBP
that/DT
there/EX
are/VBP
L/NN
SNPs/NNS
and/CC
n/NN
subjects/NNS
./.
====================
Genotypes/NNS
at/IN
SNP/NN
l/JJ
are/VBP
denoted/VBN
by/IN
Xl/JJ
,/,
where/WRB
l/JJ
=/JJ
1/CD
,/,
…/NNP
,/,
L/NN
,/,
and/CC
Y/NN
indicates/VBZ
the/DT
disease/NN
status/NN
:/:
1/CD
for/IN
case/NN
and/CC
2/CD
for/IN
control/NN
./.
====================
We/PRP
assume/VBP
that/DT
SNPs/NNS
are/VBP
bi-allelic/JJ
,/,
and/CC
capital/JJ
and/CC
lowercase/JJ
letters/NNS
always/RB
indicate/VBP
the/DT
major/JJ
and/CC
minor/JJ
alleles/NNS
,/,
respectively/RB
./.
====================
For/IN
instance/NN
,/,
AA/NN
indicates/VBZ
a/DT
homozygous/JJ
reference/VBP
genotype/NN
,/,
Aa/NNP
indicates/VBZ
the/DT
heterozygous/JJ
genotype/NN
,/,
and/CC
aa/NN
indicates/VBZ
the/DT
homozygous/JJ
variant/JJ
genotype/NN
./.
====================
For/IN
simplicity/NN
,/,
we/PRP
denote/VBP
the/DT
homozygous/JJ
reference/VBP
genotype/NN
,/,
heterozygous/JJ
genotype/NN
,/,
and/CC
homozygous/JJ
variant/JJ
genotype/NN
as/IN
1/CD
,/,
2/CD
,/,
and/CC
3/CD
,/,
respectively/RB
./.
====================
Review/NN
of/IN
BOOST/NN
====================
The/DT
logistic/JJ
regression/NN
model/NN
with/IN
only/RB
a/DT
main/JJ
effect/NN
for/IN
two/CD
SNPs/NNS
,/,
p/NN
and/CC
q/RB
,/,
can/MD
be/VB
modeled/VBN
by/IN
the/DT
following/VBG
form/VBP
:/:
logP/NN
(/(
Y=1|Xp=i/NNP
,/,
Xp=j/NNP
)/)
P/NN
(/(
Y=2|Xp=i/NNP
,/,
Xp=j/NNP
)/)
=β0+βiχp+βjχq/JJ
,/,
and/CC
denote/JJ
its/PRP$
log-likelihood/NN
as/IN
LM/NN
./.
====================
The/DT
logistic/JJ
regression/NN
model/NN
with/IN
main/JJ
effects/NNS
and/CC
interaction/NN
terms/NNS
is/VBZ
logP/NN
(/(
Y=1|Xp=i/NNP
,/,
Xq=j/NN
)/)
P/NN
(/(
Y=2|Xp=i/NNP
,/,
Xq=j/NN
)/)
=β0+βiXp+βjχq+βijχpχq/JJ
./.
====================
We/PRP
denote/VBP
it/PRP
log-likelihood/NN
value/NN
by/IN
LF/NN
./.
====================
Then/RB
,/,
the/DT
interaction/NN
effects/NNS
can/MD
be/VB
detected/VBN
by/IN
the/DT
difference/NN
of/IN
the/DT
maximum/NN
log-likelihoods/NNS
(/(
MLEs/NNS
)/)
of/IN
these/DT
two/CD
models—i.e./FW
,/,
L^F-L^M/NN
./.
====================
However/RB
,/,
the/DT
difference/NN
in/IN
the/DT
log-likelihood/NN
needs/VBZ
very/RB
intensive/JJ
computation/NN
for/IN
hundreds/VBZ
of/IN
billions/NNS
of/IN
pairs/NNS
of/IN
SNPs/NNS
./.
====================
Alternatively/RB
,/,
there/EX
exists/VBZ
a/DT
one-to-one/CD
correspondence/NN
between/IN
a/DT
logistic/JJ
regression/NN
model/NN
and/CC
a/DT
log-linear/JJ
model/NN
in/IN
categorical/JJ
data/NNS
analysis/NN
[/(
15/CD
]/)
,/,
and/CC
BOOST/NN
considers/VBZ
interaction/NN
models/NNS
based/VBN
on/IN
log-linear/JJ
models/NNS
[/(
9/CD
]/)
./.
====================
On/IN
the/DT
basis/NN
of/IN
the/DT
equivalence/NN
between/IN
the/DT
log-linear/JJ
model/NN
and/CC
its/PRP$
corresponding/JJ
logistic/JJ
regression/NN
model/NN
,/,
BOOST/NN
constructed/VBN
its/PRP$
test/NN
statistic/JJ
using/VBG
the/DT
homogeneous/JJ
association/NN
model/NN
MH/NN
and/CC
saturated/JJ
model/NN
MS/NN
and/CC
denotes/VBZ
their/PRP$
log-likelihood/NN
as/IN
LH/JJ
and/CC
LS/NN
,/,
respectively/RB
./.
====================
Then/RB
,/,
we/PRP
denote/VBP
the/DT
observed/VBN
genotype/NN
count/NN
of/IN
disease/NN
status/NN
k/VBP
with/IN
Xp/NN
=/JJ
i/LS
and/CC
Xq/NN
=/JJ
j/RB
by/IN
nijk/JJ
and/CC
the/DT
expected/VBN
genotype/NN
count/NN
by/IN
µijk/JJ
,/,
where/WRB
k/JJ
=/JJ
1/CD
or/CC
2/CD
,/,
i/LS
=/JJ
1/CD
,/,
2/CD
,/,
or/CC
3/CD
,/,
and/CC
j/RB
=/JJ
1/CD
,/,
2/CD
,/,
or/CC
3/CD
./.
====================
Then/RB
,/,
the/DT
maximum/NN
log-likelihood/NN
of/IN
both/DT
models/NNS
will/MD
be/VB
L^S=∑i/JJ
,/,
j/RB
,/,
knijklognijk-nijk-lognijk/NN
!/CD
./.
====================
If/IN
we/PRP
let/VBP
μ^ijkH/NN
be/VB
the/DT
MLE/NN
of/IN
µijk/JJ
for/IN
MH/NN
,/,
we/PRP
have/VBP
L^H=LHμ^ijkH=maxμijk∑i/JJ
,/,
j/RB
,/,
knijklogμijk-μijk-lognijk/NN
!/CD
./.
====================
The/DT
interaction/NN
effects/NNS
based/VBN
on/IN
the/DT
likelihood/NN
ratio/NN
test/NN
can/MD
be/VB
calculated/VBN
by/IN
the/DT
following/VBG
forms/NNS
:/:
L^S-L^H=∑i/NNP
,/,
j/RB
,/,
knijklognijkμ^ijkH-nijk+μ^ijkH/JJ
./.
====================
If/IN
we/PRP
let/VBP
n/NN
be/VB
the/DT
total/JJ
sample/NN
size/NN
,/,
π^ijk=nijkn/RB
and/CC
P^ijk=μ^ijkHn/NN
,/,
it/PRP
can/MD
be/VB
further/RBR
simplified/VBN
as/IN
n∑i/RB
,/,
j/RB
,/,
kπ^ijklogπ^ijkP^ijk/NN
,/,
and/CC
it/PRP
can/MD
also/RB
be/VB
denoted/VBN
by/IN
Kullback-Leibler/NN
's/POS
[/(
9/CD
]/)
form/VBP
as/IN
n·DKLπ^ijk‖P^ijk/RB
./.
====================
This/DT
provides/VBZ
another/DT
interpretation/NN
of/IN
interactions/NNS
,/,
in/IN
that/DT
the/DT
difference/NN
of/IN
two/CD
log-likelihoods/NNS
is/VBZ
proportional/JJ
to/TO
the/DT
Kullback-Leibler/NN
divergence/NN
of/IN
the/DT
joint/NN
distribution/NN
obtained/VBN
under/IN
the/DT
saturated/JJ
model/NN
MS/NN
and/CC
the/DT
distribution/NN
obtained/VBN
under/IN
homogeneous/JJ
association/NN
model/NN
MH/NN
./.
====================
In/IN
particular/JJ
,/,
there/EX
is/VBZ
no/DT
closed/VBN
form/VBP
solution/NN
for/IN
homogenous/JJ
association/NN
model/NN
MH/NN
,/,
and/CC
iterative/JJ
methods/NNS
are/VBP
needed/VBN
to/TO
calculate/JJ
the/DT
likelihood/JJ
ratio/NN
tests/NNS
./.
====================
Likelihood/NN
ratio/NN
tests/NNS
are/VBP
computationally/RB
intensive/JJ
when/WRB
facing/VBG
hundreds/VBZ
of/IN
billions/NNS
of/IN
SNP/NN
pairs/NNS
in/IN
the/DT
interaction/NN
analysis/NN
./.
====================
To/TO
address/VB
this/DT
issue/NN
,/,
BOOST/NN
uses/VBZ
Kirkwood/NN
superposition/NN
approximation/NN
(/(
KSA/NN
)/)
[/(
16/CD
]/)
to/TO
estimate/VB
under/IN
MH/NN
as/IN
p^ijkK=1ηπij.πi.kπ.jkπi..π.j.π..k/JJ
,/,
where/WRB
η=∑i/NNS
,/,
j/RB
,/,
kπij.πi.kπ.jkπi..π.j.π..k/NN
./.
====================
Therefore/RB
,/,
it/PRP
can/MD
be/VB
utilized/VBN
to/TO
approximate/VB
LH/NN
./.
====================
If/IN
we/PRP
let/VBP
LKSA/NN
be/VB
the/DT
likelihood/JJ
based/VBN
on/IN
KSA/NN
,/,
then/RB
we/PRP
get/VBP
following/VBG
equation/JJ
:/:
2L^S-L^KSA=2n·DKLπ^ijk‖p^ijkK/JJ
,/,
and/CC
it/PRP
can/MD
be/VB
calculated/VBN
easily/RB
on/IN
the/DT
basis/NN
of/IN
the/DT
contingency/NN
table/JJ
./.
====================
Through/IN
simulation/JJ
analysis/NN
by/IN
Wan/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
,/,
2L^S-L^KSA/NN
is/VBZ
known/VBN
to/TO
be/VB
an/DT
upper/JJ
bound/VBD
of/IN
2L^S-L^H/NN
,/,
and/CC
they/PRP
are/VBP
almost/RB
identical/JJ
if/IN
they/PRP
are/VBP
larger/JJR
than/IN
25/CD
./.
====================
The/DT
default/NN
value/NN
of/IN
the/DT
threshold/NN
τ/RB
in/IN
BOOST/NN
is/VBZ
30/CD
,/,
and/CC
its/PRP$
corresponding/JJ
p-value/NN
is/VBZ
4.89/CD
×/CD
10−6/CD
[/(
9/CD
]/)
./.
====================
In/IN
the/DT
screening/NN
stage/NN
of/IN
BOOST/NN
,/,
all/DT
pairwise/JJ
interactions/NNS
will/MD
be/VB
evaluated/VBN
by/IN
using/VBG
KSA/NN
./.
====================
If/IN
2L^S-L^KSA/NN
>/JJR
τ/RB
,/,
the/DT
interaction/NN
will/MD
be/VB
considered/VBN
in/IN
the/DT
next/JJ
testing/NN
stage/NN
;/:
otherwise/RB
,/,
it/PRP
will/MD
be/VB
discarded/VBN
from/IN
the/DT
analyses/NNS
./.
====================
All/DT
of/IN
the/DT
non-significant/JJ
SNP/NN
pairs/NNS
would/MD
be/VB
filtered/VBN
out/RP
in/IN
this/DT
manner/NN
in/IN
the/DT
screening/NN
stage/NN
./.
====================
Two-stage/CD
gene-gene/NN
interaction/NN
analyses/NNS
====================
We/PRP
first/RB
apply/RB
the/DT
BOOST/NN
approach/NN
to/TO
select/VB
the/DT
promising/JJ
pairs/NNS
of/IN
SNPs/NNS
with/IN
the/DT
a/DT
priori/JJ
chosen/NN
τ./FW
τ/RB
can/MD
be/VB
selected/VBN
based/VBN
on/IN
the/DT
available/JJ
computing/VBG
facility/NN
,/,
and/CC
we/PRP
set/VBP
τ/RB
=/JJ
30/CD
for/IN
our/PRP$
analyses/NNS
./.
====================
After/IN
filtering/VBG
SNP/NN
pairs/NNS
from/IN
the/DT
first/JJ
stage/NN
with/IN
BOOST/NN
,/,
we/PRP
apply/RB
the/DT
logistic/JJ
regression/NN
./.
====================
BOOST/NN
can/MD
not/RB
adjust/JJ
for/IN
the/DT
effects/NNS
of/IN
covariates/NNS
,/,
and/CC
we/PRP
applied/VBD
logistic/JJ
regression/NN
analysis/NN
with/IN
adjustments/NNS
for/IN
sex/NN
,/,
age/NN
,/,
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
and/CC
the/DT
top/NN
10/CD
principal/JJ
component/NN
(/(
PC/NN
)/)
scores/VBZ
to/TO
the/DT
selected/VBN
pairs/NNS
of/IN
SNPs/NNS
with/IN
BOOST/NN
./.
====================
The/DT
logistic/JJ
regression/NN
analysis/NN
was/VBD
performed/VBN
by/IN
using/VBG
the/DT
glm/NN
function/NN
in/IN
R/NN
software/NN
./.
====================
To/TO
calculate/VB
the/DT
p-values/NNS
of/IN
the/DT
interaction/NN
term/NN
,/,
we/PRP
used/VBD
the/DT
ANOVA/NN
function/NN
by/IN
comparing/VBG
two/CD
fitted/JJ
models/NNS
in/IN
R/NN
./.
====================
We/PRP
have/VBP
carried/VBN
out/RP
an/DT
interaction/NN
analysis/NN
on/IN
T2D/NN
in/IN
the/DT
KARE/NN
cohort/NN
on/IN
the/DT
genome-wide/NN
scale/NN
;/:
8,773/CD
subjects/NNS
with/IN
304,245/CD
SNPs/NNS
were/VBD
considered/VBN
for/IN
detecting/VBG
gene-gene/NN
interactions/NNS
./.
====================
Missing/VBG
genotypes/NNS
were/VBD
imputed/VBN
with/IN
Impute2/NN
[/(
17/CD
]/)
software/JJ
./.
====================
We/PRP
applied/VBD
the/DT
proposed/JJ
two-stage/JJ
approach/NN
to/TO
identify/VB
the/DT
genome-wide/NN
significant/JJ
gene-gene/NN
interactions/NNS
./.
====================
The/DT
analyses/NNS
were/VBD
completed/VBN
within/IN
42/CD
h/NN
with/IN
an/DT
Intel/NN
Core/NN
i3-4130/NN
CPU/NN
3.40/CD
GHz/NN
desktop/NN
./.
====================
A/DT
total/JJ
of/IN
46,282,357,890/CD
interactions/NNS
were/VBD
executed/VBN
,/,
and/CC
the/DT
Bonferroni-adjusted/JJ
0.05/CD
genome-wide/NN
significance/NN
level/NN
is/VBZ
1.08e-12/CD
./.
====================
Promising/VBG
pairs/NNS
of/IN
SNPs/NNS
were/VBD
selected/VBN
with/IN
BOOST/NN
,/,
and/CC
229,965/CD
pairs/NNS
of/IN
SNPs/NNS
were/VBD
selected/VBN
with/IN
BOOST/NN
;/:
then/RB
229,965/CD
pairs/NNS
of/IN
SNPs/NNS
were/VBD
analyzed/VBN
with/IN
logistic/JJ
regression/NN
./.
====================
To/TO
perform/VB
adjustments/NNS
for/IN
the/DT
population/NN
substructure/NN
between/IN
individuals/NNS
,/,
we/PRP
used/VBD
the/DT
EIGENSTRAT/NN
[/(
18/CD
]/)
method/NN
./.
====================
EIGENSTRAT/NN
calculates/NNS
the/DT
genetic/JJ
similarities/NNS
among/IN
subjects/NNS
by/IN
using/VBG
a/DT
genetic/JJ
relationship/NN
matrix/NN
and/CC
applies/VBZ
PC/NN
analysis/NN
./.
====================
The/DT
generated/VBN
PC/NN
scores/VBZ
are/VBP
then/RB
utilized/VBD
as/IN
covariates/VBZ
for/IN
genetic/JJ
association/NN
analyses/NNS
,/,
and/CC
this/DT
approach/NN
guarantees/NNS
robustness/NN
against/IN
a/DT
population/NN
substructure/NN
./.
====================
Here/RB
,/,
we/PRP
calculated/VBD
the/DT
first/JJ
10/CD
PC/NN
scores/VBZ
,/,
and/CC
they/PRP
were/VBD
included/VBN
as/IN
covariates/VBZ
for/IN
the/DT
logistic/JJ
method/NN
in/IN
R./NNP
Sex/NN
,/,
age/NN
,/,
and/CC
BMI/NN
were/VBD
also/RB
included/VBD
as/IN
covariates/VBZ
in/IN
the/DT
analysis/NN
./.
====================
Most/JJS
significant/JJ
results/NNS
for/IN
interaction/NN
analyses/NNS
with/IN
KARE/NN
datasets/NNS
are/VBP
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
Only/RB
the/DT
top/NN
10/CD
significant/JJ
SNP/NN
pairs/NNS
are/VBP
listed/VBN
./.
====================
The/DT
most/JJS
significant/JJ
interaction/NN
effect/NN
with/IN
a/DT
p-value/JJ
of/IN
3.11E-11/NN
was/VBD
found/VBN
for/IN
rs1402142/NN
and/CC
rs8012584/NN
./.
====================
The/DT
former/JJ
is/VBZ
associated/VBN
with/IN
the/DT
genes/NNS
HTRA3/NN
,/,
AREG/NN
,/,
TEC/NNS
,/,
and/CC
NRAS/NN
(/(
Table/JJ
2/CD
)/)
,/,
which/WDT
are/VBP
related/JJ
to/TO
metabolic/JJ
,/,
immune/JJ
,/,
and/CC
hematological/JJ
diseases/NNS
,/,
and/CC
the/DT
latter/JJ
is/VBZ
associated/VBN
with/IN
the/DT
genes/NNS
ANG/NN
and/CC
ABCB1/NN
,/,
related/JJ
to/TO
neurological/JJ
and/CC
metabolic/JJ
diseases/NNS
./.
====================
Our/PRP$
results/NNS
show/VBP
that/IN
even/RB
the/DT
interactions/NNS
are/VBP
significant/JJ
,/,
but/CC
their/PRP$
marginal/JJ
effects/NNS
may/MD
not/RB
be/VB
./.
====================
There/EX
are/VBP
some/DT
interesting/JJ
results/NNS
that/IN
rs872234/NN
is/VBZ
near/JJ
DHFRP2/NN
,/,
which/WDT
is/VBZ
related/JJ
to/TO
diabetes/NNS
mellitus/NN
type/NN
1/CD
[/(
19/CD
]/)
,/,
and/CC
rs1110144/NN
and/CC
rs1104853/NN
are/VBP
both/DT
in/IN
CNTNAP2/NN
[/(
20/CD
]/)
and/CC
MIR548T/NN
,/,
respectively/RB
;/:
they/PRP
are/VBP
also/RB
known/VBN
to/TO
be/VB
associated/VBN
with/IN
diabetes/NNS
./.
====================
The/DT
analysis/NN
of/IN
gene-gene/NN
interactions/NNS
on/IN
a/DT
genome-wide/JJ
scale/NN
is/VBZ
computationally/RB
very/RB
intensive/JJ
,/,
and/CC
many/JJ
computational/JJ
and/CC
statistical/JJ
approaches/NNS
have/VBP
been/VBN
recently/RB
proposed/VBN
to/TO
minimize/VB
the/DT
computational/JJ
burden/NN
./.
====================
We/PRP
found/VBD
that/IN
BOOST/NN
is/VBZ
highly/RB
computationally/RB
efficient/JJ
and/CC
can/MD
filter/VB
out/RP
non-significant/JJ
interaction/NN
pairs/NNS
in/IN
a/DT
fast/JJ
manner/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
proposed/VBD
an/DT
efficient/JJ
strategy/NN
to/TO
identify/VB
interactions/NNS
in/IN
genome-wide/NN
SNP/NN
data/NNS
./.
====================
We/PRP
first/RB
utilized/VBD
the/DT
screening/NN
stage/NN
of/IN
BOOST/NN
to/TO
filter/RBR
out/IN
non-significant/JJ
pairs/NNS
and/CC
then/RB
used/VBN
logistic/JJ
regression/NN
with/IN
several/JJ
covariates/NNS
,/,
such/JJ
as/IN
age/NN
,/,
sex/NN
,/,
BMI/NN
,/,
and/CC
PC/NN
scores/VBZ
./.
====================
In/IN
real/JJ
data/NNS
analysis/NN
,/,
we/PRP
used/VBD
the/DT
KARE/NN
cohort/NN
dataset/NN
to/TO
detect/VB
gene-gene/NN
interactions/NNS
of/IN
T2D/NN
./.
====================
The/DT
smallest/JJS
p-value/NN
(/(
3.11E-11/CD
)/)
of/IN
interaction/NN
pairs/NNS
in/IN
the/DT
KARE/NN
data/NNS
was/VBD
found/VBN
for/IN
rs1402142/NN
and/CC
rs8012584/NN
./.
====================
The/DT
Bonferroni-adjusted/JJ
genome-wide/NN
significance/NN
level/NN
is/VBZ
1.08e-12/CD
,/,
and/CC
this/DT
SNP/NN
pair/NN
is/VBZ
not/RB
significant/JJ
genome-wide/NN
./.
====================
This/DT
insignificance/NN
is/VBZ
partially/RB
attributable/JJ
to/TO
the/DT
insufficient/JJ
sample/NN
size/NN
./.
====================
With/IN
advances/NNS
in/IN
genotyping/sequencing/VBG
technology/NN
,/,
genotyping/VBG
costs/NNS
will/MD
be/VB
much/RB
lower/JJR
,/,
and/CC
therefore/RB
,/,
in/IN
the/DT
near/JJ
future/JJ
,/,
sufficiently/RB
large/JJ
samples/NNS
will/MD
become/VB
available/JJ
for/IN
genegene/NN
interaction/NN
analyses/NNS
,/,
which/WDT
may/MD
lead/VB
us/PRP
to/TO
a/DT
better/RBR
understanding/NN
of/IN
human/JJ
diseases/NNS
./.
====================
Results/NNS
for/IN
top/NN
10/CD
highest/JJS
interaction/NN
p-values/NNS
between/IN
two/CD
SNPs/NNS
in/IN
the/DT
KARE/NN
dataset/NN
====================
The/DT
association/NN
genes/NNS
of/IN
the/DT
SNPs/NNS
of/IN
the/DT
top/NN
10/CD
highest/JJS
p-value/JJ
interaction/NN
pairs/NNS
====================
